Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Expression of aspartoacylase (ASPA) and Canavan disease.
Sommer A, Sass JO.
Gene. 2012 Sep 1;505(2):206-10. doi: 10.1016/j.gene.2012.06.036. Epub 2012 Jun 28.
Related citations
A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH, Iscan A, Cece H, Calik M.
Genet Couns. 2012;23(1):9-12.
Lithium citrate as treatment of Canavan disease.
Solsona MD, Fernández LL, Boquet EM, Andrés JL.
Clin Neuropharmacol. 2012 May;35(3):150-1. doi: 10.1097/WNF.0b013e3182515c9d.
A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
Durmaz AA, Akin H, Onay H, Vahabi A, Ozkinay F.
Fetal Pediatr Pathol. 2012 Aug;31(4):236-9. doi: 10.3109/15513815.2011.650292. Epub 2012 Apr 2.
A missense mutation (p.G274R) in gene ASPA causes Canavan disease in a Pakistani family.
Hussain R, Daud S, Kakar N, Ahmad A, Baloch AH, Tareen AM, Kakar MA, Ahmad J.
Mol Biol Rep. 2012 May;39(5):6197-201. doi: 10.1007/s11033-011-1438-2. Epub 2012 Jan 5.
Chromosomal 17p13.3 microdeletion unmasking recessive Canavan disease mutation.
Cozzolino M, Augello B, Carella M, Palumbo O, Tavazzi B, Amorini AM, Lazzarino G, Merla G, Brunetti-Pierri N.
Mol Genet Metab. 2011 Dec;104(4):706-7. doi: 10.1016/j.ymgme.2011.09.031. Epub 2011 Oct 1. No abstract available.
Canavan disease: a novel mutation.
Schober H, Luetschg J, Hoeliner I, Kalb S, Simma B.
Pediatr Neurol. 2011 Oct;45(4):256-8. doi: 10.1016/j.pediatrneurol.2011.06.011.
A safety trial of high dose glyceryl triacetate for Canavan disease.
Segel R, Anikster Y, Zevin S, Steinberg A, Gahl WA, Fisher D, Staretz-Chacham O, Zimran A, Altarescu G.
Mol Genet Metab. 2011 Jul;103(3):203-6. doi: 10.1016/j.ymgme.2011.03.012. Epub 2011 Mar 15.
Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.
Zano S, Malik R, Szucs S, Matalon R, Viola RE.
Mol Genet Metab. 2011 Feb;102(2):176-80. doi: 10.1016/j.ymgme.2010.10.012. Epub 2010 Oct 30.
Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
Surendran S.
Med Hypotheses. 2010 Dec;75(6):533-4. doi: 10.1016/j.mehy.2010.07.017. Epub 2010 Jul 31.
Elevated CSF N-acetylaspartylglutamate suggests specific molecular diagnostic abnormalities in patients with white matter diseases.
Mochel F, Boildieu N, Barritault J, Sarret C, Eymard-Pierre E, Seguin F, Schiffmann R, Boespflug-Tanguy O.
Biochim Biophys Acta. 2010 Nov;1802(11):1112-7. doi: 10.1016/j.bbadis.2010.07.005. Epub 2010 Jul 13.
Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
Colaianni A, Chandrasekharan S, Cook-Deegan R.
Genet Med. 2010 Apr;12(4 Suppl):S5-S14. doi: 10.1097/GIM.0b013e3181d5a669.
Two novel missense mutations in the aspartoacylase gene in a Chinese patient with congenital Canavan disease.
Zhang H, Liu X, Gu X.
Brain Dev. 2010 Nov;32(10):879-82. doi: 10.1016/j.braindev.2010.01.001. Epub 2010 Feb 2.
Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease.
Assadi M, Janson C, Wang DJ, Goldfarb O, Suri N, Bilaniuk L, Leone P.
Eur J Paediatr Neurol. 2010 Jul;14(4):354-9. doi: 10.1016/j.ejpn.2009.11.006. Epub 2010 Jan 19.
A 439 kb-sized homozygous deletion in 17p13.3 leading to biallelic loss of the ASPA as cause of Canavan disease detected by SNP-array analysis.
Caliebe A, Vater I, Plendl H, Gesk S, Siebert R, Cremer FW, Klein-Hitpass L.
Mol Genet Metab. 2010 Feb;99(2):184-5. doi: 10.1016/j.ymgme.2009.10.011. Epub 2009 Oct 20. No abstract available.
Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model.
Madhavarao CN, Arun P, Anikster Y, Mog SR, Staretz-Chacham O, Moffett JR, Grunberg NE, Gahl WA, Namboodiri AM.
J Inherit Metab Dis. 2009 Oct;32(5):640-50. doi: 10.1007/s10545-009-1155-3. Epub 2009 Aug 15.
Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH, Guilfoyle DN.
Neurochem Res. 2009 Sep;34(9):1523-34. doi: 10.1007/s11064-009-9958-z. Epub 2009 Mar 25.
Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry.
Al-Dirbashi OY, Kurdi W, Imtiaz F, Ahmad AM, Al-Sayed M, Tulbah M, Al-Nemer M, Rashed MS.
Prenat Diagn. 2009 May;29(5):477-80. doi: 10.1002/pd.2223.
Genome-wide gene expression profiling and mutation analysis of Saudi patients with Canavan disease.
Kaya N, Imtiaz F, Colak D, Al-Sayed M, Al-Odaib A, Al-Zahrani F, Al-Mubarak BR, Al-Owain M, Al-Dhalaan H, Chedrawi A, Al-Hassnan Z, Coskun S, Sakati N, Ozand P, Meyer BF.
Genet Med. 2008 Sep;10(9):675-84. doi: 10.1097GIM.0b013e31818337a8.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on